K.CombrinckS.ViljoenA
Ocrevus (ocrelizumab) Disease area(s): Neurology/immunology Manufacturer(s): Roche 2024 Sales (USD): $7.66 billion Why it sold so well: In 2024, Roches multiple sclerosis (MS) therapy Ocrevus achieved sales of CHF 6.74 billion ($7.66 billion), marking a 9% increase from the previous year
It also made the purification of insulin preparations much easier and was a key stepping stone to the biosynthetic production of human insulin (Philipson, Bell, Polonsky)
This hormone slows gastric emptying, increases satiety, and enhances insulin sensitivity, all of which contribute to weight loss
The KDs clinical efficacy in the treatment of various epilepsies may be mediated in part due to its apparent ability to activate nrf2 (Milder et al., 2010)
By prioritizing these tools, we empower patients with knowledge about their health, fostering trust and collaboration